Loading stock data…
$1.30+0.33 (+34.65%)
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally.
MaxCyte, Inc. in the Healthcare sector is trading at $1.30 with a market capitalization of $112M. Wall Street consensus targets $4.11 (4 analysts), implying a +216.3% move over the next 12 months. The stock is currently 30% below its 52-week high of $1.86, remaining 22.5% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.27M↓ | $9.65M↑ | $7.30M↑ | $6.83M↓ | $8.51M |
| Gross Profit | $5.60M↓ | $8.08M↑ | $5.69M↑ | $5.23M↓ | $6.99M |
| Operating Income | -$10.23M↓ | -$6.18M↑ | -$7.67M↑ | -$11.09M↑ | -$14.23M |
| Net Income | -$8.87M↓ | -$4.75M↑ | -$9.60M↑ | -$12.42M↓ | -$12.36M |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale t...